Gesine Meyer-Rath

Gesine Meyer-Rath, MD, PhD

Research Associate Professor, Global Health - Boston University School of Public Health


Dr Meyer-Rath is a Research Associate Professor at the Department of Global Health of the Boston University School of Public Health. She is a physician and health economist working on the economics of HIV and COVID-19 in low- and middle-income countries. Her focus lies on modeling methods for economic evaluation, including infectious disease modeling and decision analysis, and translating research into recommendations for public policy. Before joining BUSPH she has worked in the Pediatrics Department of Charité University Hospital Berlin, at the World Health Organization and at the London School of Hygiene and Tropical Medicine.

Dr Meyer-Rath is based in Johannesburg where she works at the Health Economics and Epidemiology Research Office (HE2RO), a collaboration between Boston University and the University of the Witwatersrand. She holds a PhD in Health Economics from the London School of Hygiene and Tropical Medicine as well as a MD/PhD in Physiology from Free University Berlin.

Other Positions

  • Center Faculty Member, Global Health - Boston University School of Public Health


  • Freie Universität Berlin, MD Field of Study: Medicine
  • Freie Universität Berlin, PhD Field of Study: Physiology



  • Published on 1/12/2023

    Smith J, Bansi-Matharu L, Cambiano V, Dimitrov D, Bershteyn A, van de Vijver D, Kripke K, Revill P, Boily MC, Meyer-Rath G, Taramusi I, Lundgren JD, van Oosterhout JJ, Kuritzkes D, Schaefer R, Siedner MJ, Schapiro J, Delany-Moretlwe S, Landovitz RJ, Flexner C, Jordan M, Venter F, Radebe M, Ripin D, Jenkins S, Resar D, Amole C, Shahmanesh M, Gupta RK, Raizes E, Johnson C, Inzaule S, Shafer R, Warren M, Stansfield S, Paredes R, Phillips AN. Predicted effects of the introduction of long-acting injectable cabotegravir pre-exposure prophylaxis in sub-Saharan Africa: a modelling study. Lancet HIV. 2023 Jan 12. PMID: 36642087.

    Read At: PubMed
  • Published on 12/20/2022

    Bansi-Matharu L, Mudimu E, Martin-Hughes R, Hamilton M, Johnson L, Ten Brink D, Stover J, Meyer-Rath G, Kelly SL, Jamieson L, Cambiano V, Jahn A, Cowan FM, Mangenah C, Mavhu W, Chidarikire T, Toledo C, Revill P, Sundaram M, Hatzold K, Yansaneh A, Apollo T, Kalua T, Mugurungi O, Kiggundu V, Zhang S, Nyirenda R, Phillips A, Kripke K, Bershteyn A. Cost-effectiveness of voluntary medical male circumcision for HIV prevention across sub-Saharan Africa: results from five independent models. Lancet Glob Health. 2023 Feb; 11(2):e244-e255. PMID: 36563699.

    Read At: PubMed
  • Published on 12/12/2022

    Masuku SD, Lekodeba N, Meyer-Rath G. The costs of interventions for type 2 diabetes mellitus, hypertension and cardiovascular disease in South Africa - a systematic literature review. BMC Public Health. 2022 Dec 12; 22(1):2321. PMID: 36510178.

    Read At: PubMed
  • Published on 11/7/2022

    Jamieson L, Johnson LF, Nichols BE, Delany-Moretlwe S, Hosseinipour MC, Russell C, Meyer-Rath G. Relative cost-effectiveness of long-acting injectable cabotegravir versus oral pre-exposure prophylaxis in South Africa based on the HPTN 083 and HPTN 084 trials: a modelled economic evaluation and threshold analysis. Lancet HIV. 2022 Dec; 9(12):e857-e867. PMID: 36356603.

    Read At: PubMed
  • Published on 9/1/2022

    Bershteyn A, Jamieson L, Kim HY, Platais I, Milali MP, Mudimu E, Ten Brink D, Martin-Hughes R, Kelly SL, Phillips AN, Bansi-Matharu L, Cambiano V, Revill P, Meyer-Rath G, Nichols BE. Transmission reduction, health benefits, and upper-bound costs of interventions to improve retention on antiretroviral therapy: a combined analysis of three mathematical models. Lancet Glob Health. 2022 09; 10(9):e1298-e1306. PMID: 35961353.

    Read At: PubMed
  • Published on 5/31/2022

    Silal SP, Groome MJ, Govender N, Pulliam JRC, Ramadan OP, Puren A, Jassat W, Leonard E, Moultrie H, Meyer-Rath KG, Ramkrishna W, Langa T, Furumele T, Moonasar D, Cohen C, Walaza S. Leveraging epidemiology as a decision support tool during the COVID-19 epidemic in South Africa. S Afr Med J. 2022 May 31; 112(5b):361-365. PMID: 35783465.

    Read At: PubMed
  • Published on 5/1/2022

    Phillips AN, Bershteyn A, Revill P, Bansi-Matharu L, Kripke K, Boily MC, Martin-Hughes R, Johnson LF, Mukandavire Z, Jamieson L, Meyer-Rath G, Hallett TB, Ten Brink D, Kelly SL, Nichols BE, Bendavid E, Mudimu E, Taramusi I, Smith J, Dalal S, Baggaley R, Crowley S, Terris-Prestholt F, Godfrey-Faussett P, Mukui I, Jahn A, Case KK, Havlir D, Petersen M, Kamya M, Koss CA, Balzer LB, Apollo T, Chidarikire T, Mellors JW, Parikh UM, Godfrey C, Cambiano V. Cost-effectiveness of easy-access, risk-informed oral pre-exposure prophylaxis in HIV epidemics in sub-Saharan Africa: a modelling study. Lancet HIV. 2022 May; 9(5):e353-e362. PMID: 35489378.

    Read At: PubMed
  • Published on 3/31/2022

    Benade M, Long L, Rosen S, Meyer-Rath G, Tucker JM, Miot J. Reduction in initiations of HIV treatment in South Africa during the COVID pandemic. BMC Health Serv Res. 2022 Mar 31; 22(1):428. PMID: 35361209.

    Read At: PubMed
  • Published on 2/7/2022

    Johnson LF, Meyer-Rath G, Dorrington RE, Puren A, Seathlodi T, Zuma K, Feizzadeh A. The Effect of HIV Programs in South Africa on National HIV Incidence Trends, 2000-2019. J Acquir Immune Defic Syndr. 2022 Jun 01; 90(2):115-123. PMID: 35125471.

    Read At: PubMed
  • Published on 12/15/2021

    Jamieson L, Serenata C, Makhubele L, Sokhela S, Mashabane N, Akpomiemie G, Johnson LF, Venter WDF, Meyer-Rath G. Cost and cost-effectiveness of dolutegravir-based antiretroviral regimens: an economic evaluation of a clinical trial. AIDS. 2021 12 15; 35(Suppl 2):S173-S182. PMID: 34848584.

    Read At: PubMed

News & In the Media